

A
B
Compound 19
Scopolamine
Compound 3
Scopolamine
dose (mg/kg)

FIG. 1



Discrimination index (d2)
0.50
0.40
0.30
0.20
0.10
0.00
Compound 32
MDL100907
Scopolamine
0 0 0 0 1 3 1 3 1 3
0 0 0.1 0.3 0 0 0.1 0.1 0.3 0.3
0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
**
*
*
*
*
**

FIG. 2



A
Increase in fEPSP slope
relative to baseline
100 nM Compound 32
0.5 s @ 50 Hz
n = 5 slices
p > 0.05
Time (min)
Increase in fEPSP slope
relative to baseline
100 nM MDL 100907
0.5 s @ 50 Hz
n = 6 slices
p < 0.01
Time (min)
B
Increase in fEPSP slope over baseline
untreated control
MDL 100907 (0.1uM)
SR46349 (10uM)
Olanzapine (1uM)
Compound 3 (1uM)
Compound 18 (1uM)
Compound 32 (0.1 uM)
*p<0.05

FIG. 3